{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T09:05:57Z","timestamp":1753520757694,"version":"3.40.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>The nodal positivity in advanced ovarian cancers is approximately 68\u201370% histopathologically. Even after neoadjuvant chemotherapy (NACT) chance of nodal positivity is around 50\u201380%. In the prevailing literature, the nodal burden is a neglected entity in both assessment and documentation and complete clearance during the CRS. We aim to highlight the importance of nodal dissection and propose a Nodal Cancer Index (NCI) like PCI for ovarian cancers based on our experience of 105 cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>We included 105 patients with advanced ovarian cancers who underwent CRS. Retroperitoneal lymph nodes and bilateral pelvic lymph node dissection were routinely done in all the cases. For Nodal Cancer Index calculation, the abdomen is divided into 13 zones, zones 1\u20136 for retroperitoneum, zones 1\u20136 for Pelvic nodes, and zone 0 for extra-abdominal nodes. Furthermore, a Nodal size score ranging from 1 to 3 has been proposed so that the Nodal Cancer Index ranges from 13 to 39.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median age of the patients was 51\u00a0years (range 19\u201371) and the most significant patients were in stage III (65.7%), and 34.3% had stage IV disease at presentation. The lymph nodes were found to be positive in 62 patients (59%), and the positivity rate was higher in patients who underwent upfront surgery 36 (58.1%) as compared to 26 (41.9%) in those who received NACT. The majority of the patients (56.6%) had positive lymph nodes in both the pelvic and retroperitoneal groups, whereas 19.3% had only pelvic nodes positive, and 24.2% had only retroperitoneal nodes positive. The probability of overall survival at 5\u00a0years in our patients was 48.9% (95% CI\u2009=\u200935.5\u201361).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The results of our analytic observation confirm that systemic lymphadenectomy of all 13 zones proposed by our study should be an integral part of optimal CRS in the advanced carcinoma ovary and this will help us manage these advanced cases in a better objective manner.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s43046-025-00256-4","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:37:36Z","timestamp":1744371456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Proposed Nodal Cancer Index (NCI) in ovarian carcinomatosis"],"prefix":"10.1186","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7059-5383","authenticated-orcid":false,"given":"M D","family":"Ray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4403-9831","authenticated-orcid":false,"given":"Manish Kumar","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"2","key":"256_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/s0301-2115(96)02679-6","volume":"72","author":"DDM Braat","year":"1997","unstructured":"Braat DDM. Diagnosis and management of ovarian disorders. Eur J Obstet Gynecol Reprod Biol. 1997;72(2):217. https:\/\/doi.org\/10.1016\/s0301-2115(96)02679-6.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"January","key":"256_CR2","first-page":"9","volume":"6","author":"MD Ray","year":"2020","unstructured":"Ray MD, Kuppusamy R, Kumar N, Garg R. Cytoreductive surgery with hyperthermic thoracoabdominal chemotherapy in stage IV ovarian cancer - a technical description. J Cancer Metastasis Treat. 2020;6(January):9.","journal-title":"J Cancer Metastasis Treat."},{"issue":"4","key":"256_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40944-017-0158-5","volume":"15","author":"N Khalid","year":"2017","unstructured":"Khalid N, Dessai SB, Anilkumar B, et al. Clinical significance of nodal positivity following neoadjuvant chemotherapy in epithelial ovarian cancer. Indian J Gynecol Oncol. 2017;15(4):1\u20137. https:\/\/doi.org\/10.1007\/s40944-017-0158-5.","journal-title":"Indian J Gynecol Oncol"},{"issue":"4","key":"256_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3892\/mco.2016.982","volume":"5","author":"C Bachmann","year":"2016","unstructured":"Bachmann C, Bachmann R, Kraemer B, et al. Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer. Mol Clin Oncol. 2016;5(4):483\u20137. https:\/\/doi.org\/10.3892\/mco.2016.982.","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"256_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1089\/gyn.2020.0051","volume":"36","author":"MD Ray","year":"2020","unstructured":"Ray MD, Kumar N. High alert zones in nerve-sparing retroperitoneal lymph node dissection in gynecologic cancers: a precise anatomy and safe surgical technique. J Gynecol Surg. 2020;36(6):331\u20136. https:\/\/doi.org\/10.1089\/gyn.2020.0051.","journal-title":"J Gynecol Surg"},{"issue":"6","key":"256_CR6","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"BA Du","year":"2009","unstructured":"Du BA, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzin. Cancer. 2009;115(6):1234\u201344. https:\/\/doi.org\/10.1002\/cncr.24149.","journal-title":"Cancer"},{"issue":"4","key":"256_CR7","first-page":"974","volume":"170","author":"WJ Hoskins","year":"1994","unstructured":"Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary. AmJObstetGynecol. 1994;170(4):974\u20139.","journal-title":"AmJObstetGynecol"},{"issue":"8","key":"256_CR8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/IGC.0b013e31826a3559","volume":"22","author":"M Luyckx","year":"2012","unstructured":"Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in patients with figo stage iiic to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective french multicentric study. Int J Gynecol Cancer. 2012;22(8):1337\u201343. https:\/\/doi.org\/10.1097\/IGC.0b013e31826a3559.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"256_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3802\/jgo.2018.29.e47","volume":"29","author":"AA Elzarkaa","year":"2018","unstructured":"Elzarkaa AA, Shaalan W, Elemam D, et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol. 2018;29(4):1\u201310. https:\/\/doi.org\/10.3802\/jgo.2018.29.e47.","journal-title":"J Gynecol Oncol"},{"issue":"8","key":"256_CR10","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1245\/s10434-014-4329-7","volume":"22","author":"K Gasimli","year":"2015","unstructured":"Gasimli K, Braicu EI, Richter R, Chekerov R, Sehouli J. Prognostic and predictive value of the peritoneal cancer index in primary advanced epithelial ovarian cancer patients after complete cytoreductive surgery: study of tumor bank ovarian cancer. Ann Surg Oncol. 2015;22(8):2729\u201337. https:\/\/doi.org\/10.1245\/s10434-014-4329-7.","journal-title":"Ann Surg Oncol"},{"key":"256_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res"},{"issue":"1","key":"256_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/ejso.2002.1380","volume":"29","author":"AAK Tentes","year":"2003","unstructured":"Tentes AAK, Tripsiannis G, Markakidis SK, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol. 2003;29(1):69\u201373. https:\/\/doi.org\/10.1053\/ejso.2002.1380.","journal-title":"Eur J Surg Oncol"},{"key":"256_CR13","doi-asserted-by":"publisher","unstructured":"Burghardt E, Pickel H, Lahousen M, Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol. 1986;155(2):315\u20139.\u00a0https:\/\/doi.org\/10.1016\/0002-9378(86)90817-3.","DOI":"10.1016\/0002-9378(86)90817-3"},{"issue":"6","key":"256_CR14","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1525-1438.2007.00931.x","volume":"17","author":"P Harter","year":"2007","unstructured":"Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17(6):1238\u201344. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.00931.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"256_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/jnci\/dji102","volume":"97","author":"PB Panici","year":"2005","unstructured":"Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97(8):560\u20136. https:\/\/doi.org\/10.1093\/jnci\/dji102.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"256_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3802\/jgo.2021.32.e40","volume":"32","author":"T Deng","year":"2021","unstructured":"Deng T, Huang Q, Wan T, et al. The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer. J Gynecol Oncol. 2021;32(3):1\u201310. https:\/\/doi.org\/10.3802\/jgo.2021.32.e40.","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"256_CR17","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/sj.bjc.6603803","volume":"96","author":"JK Chan","year":"2007","unstructured":"Chan JK, Urban R, Hu JM, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: A study of 13 918 patients. Br J Cancer. 2007;96(12):1817\u201322. https:\/\/doi.org\/10.1038\/sj.bjc.6603803.","journal-title":"Br J Cancer"},{"issue":"1","key":"256_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1046\/j.1525-1438.1997.00418.x","volume":"7","author":"C Scarabelli","year":"1997","unstructured":"Scarabelli C, Gallo A, Visentin MC, Canzonieri V, Carbone A, Zarrelli A. Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. Int J Gynecol Cancer. 1997;7(1):18\u201326. https:\/\/doi.org\/10.1046\/j.1525-1438.1997.00418.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"256_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1006\/gyno.1996.0249","volume":"62","author":"F Di Re","year":"1996","unstructured":"Di Re F, Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: Prognostic significance of node metastases. Gynecol Oncol. 1996;62(3):360\u20135. https:\/\/doi.org\/10.1006\/gyno.1996.0249.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"256_CR20","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.ajog.2006.06.068","volume":"195","author":"GD Aletti","year":"2006","unstructured":"Aletti GD, Dowdy S, Podratz KC, Cliby WA. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. Am J Obstet Gynecol. 2006;195(6):1862\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2006.06.068.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"256_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ygyno.2012.05.014","volume":"126","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Bristow RE, Ryu HS. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecol Oncol. 2012;126(3):381\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2012.05.014.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"256_CR22","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/nejmoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822\u201332. https:\/\/doi.org\/10.1056\/nejmoa1808424.","journal-title":"N Engl J Med"},{"issue":"1","key":"256_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0950-3552(89)80051-3","volume":"3","author":"E Burghardt","year":"1989","unstructured":"Burghardt E, Winter R. The effect of chemotherapy on lymph node metastases in ovarian cancer. Baillieres Clin Obstet Gynaecol. 1989;3(1):167\u201371. https:\/\/doi.org\/10.1016\/S0950-3552(89)80051-3.","journal-title":"Baillieres Clin Obstet Gynaecol"},{"issue":"2","key":"256_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1006\/gyno.1998.4964","volume":"69","author":"G Baiocchi","year":"1998","unstructured":"Baiocchi G, Grosso G, di Re E, Fontanelli R, Raspagliesi F, di Re F. Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer. Gynecol Oncol. 1998;69(2):151\u20136. https:\/\/doi.org\/10.1006\/gyno.1998.4964.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"256_CR25","first-page":"169","volume":"25","author":"P Morice","year":"2004","unstructured":"Morice P, Joulie F, Rey A, Atallah D, Camatte S, Pautier P, Thoury A, Lhomm\u00e9 C, Duvillard P, Castaigne D. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol. 2004;25(2):169\u201374.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"256_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.gyobfe.2004.04.009","volume":"32","author":"F Joulie","year":"2004","unstructured":"Joulie F, Morice P, Rey A, Thoury A, Camatte S, Pautier P, Lhomm\u00e9 C, Haie-Meder C, Duvillard P, Castaigne D. Are nodal metastases in ovarian cancer chemoresistant lesions? Comparative study of initial lymphadenectomy or after chemotherapy. Gynecol Obstet Fertil. 2004;32(6):502\u20137. https:\/\/doi.org\/10.1016\/j.gyobfe.2004.04.009. French.","journal-title":"Gynecol Obstet Fertil."},{"issue":"3","key":"256_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/jso.24669","volume":"116","author":"KJ Eoh","year":"2017","unstructured":"Eoh KJ, Yoon JW, Lee I, et al. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. J Surg Oncol. 2017;116(3):329\u201336. https:\/\/doi.org\/10.1002\/jso.24669.","journal-title":"J Surg Oncol"},{"key":"256_CR28","doi-asserted-by":"publisher","unstructured":"Yang L, Zhang B, Xing G, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome. PLoS One. 2017;12(10):e0186725.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0186725. Published 2017 Oct 23","DOI":"10.1371\/journal.pone.0186725"},{"issue":"4","key":"256_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3802\/jgo.2015.26.4.303","volume":"26","author":"H Iwase","year":"2015","unstructured":"Iwase H, Takada T, Iitsuka C, et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. J Gynecol Oncol. 2015;26(4):303\u201310. https:\/\/doi.org\/10.3802\/jgo.2015.26.4.303.","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"256_CR30","first-page":"1815","volume":"36","author":"MD Keyver-Paik","year":"2016","unstructured":"Keyver-Paik MD, Arden JM, L\u00fcders C, et al. Impact of chemotherapy on retroperitoneal lymph nodes in ovarian cancer. Anticancer Res. 2016;36(4):1815\u201324.","journal-title":"Anticancer Res"},{"key":"256_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1072-7515(03)00234-5","volume":"197","author":"P Morice","year":"2003","unstructured":"Morice P, Joulie F, Camatte S, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003;197:198\u2013205.","journal-title":"J Am Coll Surg"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00256-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00256-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T11:37:37Z","timestamp":1744371457000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-025-00256-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00256-4","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"18 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of All India Institute of Medical Sciences, Delhi, India. The patients\/participants provided their written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}